Beta Bionics, Inc. (BBNX)

Market Cap	991.38M +8.9%
Revenue (ttm)	127.27M +43.7%
Net Income	-83.12M
EPS	-1.85
Shares Out	54.37M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	266,342
Open	17.85
Previous Close	17.85
Day's Range	17.77 - 18.94
52-Week Range	8.80 - 32.71
Beta	n/a
Analysts	Buy
Price Target	25.10 (+37.65%)
Earnings Date	Oct 27, 2026

About BBNX

Beta Bionics, Inc., a commercial-stage medical device company, engages in the design, development, and commercialization of solutions to enhance the health and quality of life of insulin-requiring people with diabetes. It offers iLet Bionic Pancreas, an insulin delivery device for the treatment of type 1 diabetes in adults and children six years of age and older. The company is also developing Patch Pump, an insulin pump that is designed to adhere directly to the skin and administer insulin without the need for tubing; Bihormonal iLet, which co...

• Industry: Medical Devices
• Sector: Healthcare
• IPO Date: Jan 30, 2025
• Employees: 423
• Stock Exchange: Nasdaq
• Ticker Symbol: BBNX
• Website: https://www.betabionics.com

Financial Performance

In 2025, Beta Bionics's revenue was $100.25 million, an increase of 53.94% compared to the previous year's $65.12 million. Losses were -$73.20 million, 33.7% more than in 2024.

Analyst Summary

According to 15 analysts, the average rating for BBNX stock is "Buy." The 12-month stock price target is $25.1, which is an increase of 37.65% from the latest price.

Price Target

$25.1

(37.65% upside)

Analyst Consensus: Buy

Data Sources: S&P Global Market Intelligence, CBOE, and more

Fundamental and historical data is provided by S&P Global Market Intelligence. Real-time stock price data is provided by CBOE and 15-minute delayed consolidated tape pricing data is provided by Nasdaq UTP.

Last checked:

Oct 29, 2026

Data Sources Report a data error